Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report released on Monday. The brokerage issued a hold rating on the medical research company’s stock.

Separately, BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a research report on Wednesday, December 11th.

Accelerate Diagnostics Stock Performance

Shares of Accelerate Diagnostics stock opened at $1.09 on Monday. Accelerate Diagnostics has a 1 year low of $0.73 and a 1 year high of $2.09. The company has a market capitalization of $27.30 million, a P/E ratio of -0.38 and a beta of 0.55. The company’s fifty day moving average is $1.17 and its two-hundred day moving average is $1.47.

Institutional Trading of Accelerate Diagnostics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Accelerate Diagnostics in the third quarter valued at about $34,000. Jane Street Group LLC purchased a new stake in shares of Accelerate Diagnostics in the fourth quarter valued at about $27,000. Renaissance Technologies LLC boosted its holdings in shares of Accelerate Diagnostics by 160.6% in the fourth quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock valued at $128,000 after acquiring an additional 65,984 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Accelerate Diagnostics by 6.9% in the fourth quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 8,777 shares in the last quarter. Hedge funds and other institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.